EdgeMarket › What Mpm Bioimpact Llc reported owning
What Mpm Bioimpact Llc reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
1.3BPositions
41Quarter
2026-03-31Shown below
41largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| DBVT DBV Technologies S.A. | 108.9M | 8.4% | 5.2M | 14.55 | +48.5% |
| CGEM Cullinan Therapeutics, Inc. | 108.7M | 8.4% | 7.6M | 21.68 | +190.2% |
| AKTS Aktis Oncology, Inc. | 86.5M | 6.7% | 4.8M | 24.07 | +19858.5% |
| LQDA Liquidia Corp | 53.0M | 4.1% | 1.4M | 68.62 | +150.9% |
| ALMS ALUMIS INC. | 52.6M | 4.1% | 2.4M | 24.17 | +448.1% |
| EWTX Edgewise Therapeutics, Inc. | 52.3M | 4.0% | 1.7M | 44.18 | +219.2% |
| RVMD Revolution Medicines, Inc. | 49.3M | 3.8% | 506.8K | 209.46 | +479.3% |
| AGIO AGIOS PHARMACEUTICALS, INC. | 44.2M | 3.4% | 1.3M | 33.09 | -10.1% |
| CORT CORCEPT THERAPEUTICS INC | 39.7M | 3.1% | 985.7K | 122.25 | +73.7% |
| TRVI Trevi Therapeutics, Inc. | 39.4M | 3.0% | 3.3M | 17.96 | +142.0% |
| DNTH Dianthus Therapeutics, Inc. /DE/ | 35.6M | 2.7% | 424.0K | 111.10 | +374.4% |
| XENE Xenon Pharmaceuticals Inc. | 34.2M | 2.6% | 588.7K | 60.77 | +61.5% |
| MLTX MoonLake Immunotherapeutics | 33.8M | 2.6% | 1.8M | 15.76 | -70.9% |
| TVTX Travere Therapeutics, Inc. | 33.7M | 2.6% | 1.1M | 65.71 | +265.7% |
| EVMN Evommune, Inc. | 33.5M | 2.6% | 1.5M | 14.02 | — |
| CYTK CYTOKINETICS INC | 33.0M | 2.5% | 500.0K | 76.84 | +105.9% |
| SNDX Syndax Pharmaceuticals Inc | 31.3M | 2.4% | 1.3M | 19.65 | +24.8% |
| CNTX Context Therapeutics Inc. | 28.0M | 2.2% | 10.7M | 0.50 | -44.7% |
| FBRX Forte Biosciences, Inc. | 25.9M | 2.0% | 1.0M | 76.92 | +554.1% |
| PVLA PALVELLA THERAPEUTICS, INC. | 25.7M | 2.0% | 206.4K | 142.04 | +181.6% |
| DYN Dyne Therapeutics, Inc. | 25.5M | 2.0% | 1.4M | 26.10 | +118.0% |
| STOK Stoke Therapeutics, Inc. | 25.0M | 1.9% | 767.0K | 32.29 | +67.1% |
| CRVS Corvus Pharmaceuticals, Inc. | 24.5M | 1.9% | 1.7M | 14.46 | +178.6% |
| RLAY Relay Therapeutics, Inc. | 23.5M | 1.8% | 2.4M | 19.44 | +471.8% |
| TARS Tarsus Pharmaceuticals, Inc. | 23.1M | 1.8% | 329.8K | 72.70 | +31.2% |
| ORIC Oric Pharmaceuticals, Inc. | 22.9M | 1.8% | 1.8M | 14.20 | +49.3% |
| QURE uniQure N.V. | 22.4M | 1.7% | 1.4M | 48.37 | +212.5% |
| GLUE Monte Rosa Therapeutics, Inc. | 19.4M | 1.5% | 1.2M | 14.30 | +222.8% |
| NTRA Natera, Inc. | 18.6M | 1.4% | 93.1K | 332.03 | +106.7% |
| CLYM Climb Bio, Inc. | 17.8M | 1.4% | 2.6M | 17.28 | +668.0% |
| ARQT Arcutis Biotherapeutics, Inc. | 17.3M | 1.3% | 734.0K | 25.08 | +58.8% |
| URGN UroGen Pharma Ltd. | 17.0M | 1.3% | 943.8K | 46.86 | +142.7% |
| DRUG BRIGHT MINDS BIOSCIENCES INC. | 15.5M | 1.2% | 212.2K | 77.42 | +80.0% |
| ZYME Zymeworks Inc. | 14.2M | 1.1% | 565.2K | 28.67 | +100.2% |
| BLTE BELITE BIO, INC | 14.0M | 1.1% | 88.0K | 161.06 | +154.0% |
| VRDN Viridian Therapeutics, Inc.\DE | 12.7M | 1.0% | 649.9K | 24.29 | +33.9% |
| ENGN enGene Therapeutics Inc. | 12.6M | 1.0% | 1.8M | 1.78 | -53.9% |
| ABVX Abivax S.A. | 11.9M | 0.9% | 107.3K | 114.95 | +59.9% |
| ALLO Allogene Therapeutics, Inc. | 5.5M | 0.4% | 2.2M | 2.09 | +97.2% |
| ACRS Aclaris Therapeutics, Inc. | 1.5M | 0.1% | 391.9K | 6.41 | +254.1% |
| HOWL Werewolf Therapeutics, Inc. | 1.0M | 0.1% | 1.2M | 0.87 | -29.6% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →